View Older Stories View More Recent Stories

Jan 26, 2022 08:00AM Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
Jan 26, 2022 08:00AM Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
Nov 11, 2021 05:32PM Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference
Nov 11, 2021 05:32PM Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference
Nov 9, 2021 04:01PM Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
Nov 9, 2021 04:01PM Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
Sep 22, 2021 08:03AM Cyclerion Therapeutics (CYCN) Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
Sep 22, 2021 08:00AM Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
Sep 22, 2021 08:00AM Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator
Sep 8, 2021 08:00AM Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
Sep 8, 2021 08:00AM Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences
Aug 23, 2021 05:00PM Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
Aug 23, 2021 05:00PM Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer’s Disease Summit
Jul 29, 2021 05:00PM Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Jul 29, 2021 05:00PM Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
Jul 22, 2021 04:31PM Cyclerion Therapeutics (CYCN) to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at AAIC
Jul 22, 2021 04:30PM Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conf
Jul 22, 2021 04:30PM Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conf
Jul 8, 2021 07:22PM Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership
Jul 8, 2021 04:34PM Cyclerion Therapeutics (CYCN) and Beacon Biosignals Announce Expanded Strategic Partnership
Jul 8, 2021 04:30PM Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
Jul 8, 2021 04:30PM Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership
Jun 4, 2021 08:04AM Cyclerion Therapeutics (CYCN) Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
Jun 4, 2021 08:03AM Cyclerion Therapeutics (CYCN) Announces $18 Million Private Placement of Common Stock
Jun 4, 2021 08:00AM Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
Jun 4, 2021 08:00AM Cyclerion Therapeutics Announces $18 Million Private Placement
Jun 4, 2021 08:00AM Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
Jun 4, 2021 08:00AM Cyclerion Therapeutics Announces $18 Million Private Placement
May 27, 2021 04:33PM Cyclerion Therapeutics (CYCN) Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
May 27, 2021 04:30PM Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
May 27, 2021 04:30PM Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology
May 25, 2021 07:00AM Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 25, 2021 07:00AM Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
Apr 27, 2021 09:00AM Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
Apr 27, 2021 09:00AM Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
Apr 26, 2021 08:26AM Cyclerion Therapeutics (CYCN) Announces Errol De Souza, Ph.D., to Board
Apr 26, 2021 07:00AM Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
Apr 26, 2021 07:00AM Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
Apr 21, 2021 07:30AM Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
Apr 21, 2021 07:30AM Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
Apr 20, 2021 07:00AM Cyclerion Therapeutics to Host Pipeline Update Webinar
Apr 20, 2021 07:00AM Cyclerion Therapeutics to Host Pipeline Update Webinar
Mar 18, 2021 05:02PM Cyclerion Therapeutics (CYCN) Announces Departure of Chief Medical Officer
Mar 18, 2021 05:00PM Cyclerion Therapeutics Announces Departure of Chief Medical Officer
Mar 18, 2021 05:00PM Cyclerion Therapeutics Announces Departure of Chief Medical Officer
Feb 25, 2021 07:00AM Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
Feb 25, 2021 07:00AM Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
Jan 25, 2021 07:00AM Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
Jan 25, 2021 07:00AM Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
Jan 4, 2021 07:00AM Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
View More Recent Stories View Older Stories